BioCentury
ARTICLE | Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

March 9, 2018 5:16 PM UTC

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the first cohort of a Phase I trial showing that MVT-1075 was well tolerated and accumulated on target lesions as determined by dosimetry measurements after the first dose. MVT-1075 led to two cases of stable disease. MabVax said it is now enrolling patients in the second dose cohort of the trial.

The open-label, dose-escalation, U.S. trial is enrolling about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive malignancies who have failed prior therapies. The primary endpoints are maximum tolerated dose (MTD) and safety. Secondary endpoints include pharmacokinetics, recommended Phase II dose, tumor response rate, duration of response and antibodies...

BCIQ Target Profiles

CA19.9